HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

This is a multicenter, randomized, controlled, open-label study evaluating efficacy and safety of perioperative FLOT chemotherapy plus intraoperative HIPEC versus FLOT chemotherapy alone in patients with resectable localized and locally advanced diffuse and mixed type adenocarcinoma of the stomach and Type II/III GEJ.

Trial Details

NCT ID
NCT04447352
Phase
PHASE3
Sponsor
Krankenhaus Nordwest
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • 5-Fluorouracil
  • Leucovorin
  • Oxaliplatin
  • Docetaxel
  • Cisplatin
Locations (sample)
  • Aachen, Germany|50.77664,6.08342
  • Dresden, Germany|51.05089,13.73832
  • Frankfurt, Germany|49.68333,10.53333
  • Halle, Germany|51.48158,11.97947
  • Leipzig, Germany|51.33962,12.37129

Key Eligibility Criteria

  • Histologically confirmed, medically operable, resectable diffuse or mixed type (according to Lauren's classification) adenocarcinoma of the gastroe…
  • Patient has received 3 to 6 cycles of neoadjuvant FLOT (de-escalation or dose modification allowed)
  • No preceding cytotoxic or targeted therapy other than neoadjuvant FLOT (including de-escalated or dose reduced schema) therapy
  • No prior partial or complete tumor resection

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →